Kristin Palmsten1, Avanthi Hulugalle1,2, Gretchen Bandoli1, Grace M Kuo3,4, Shayda Ansari1, Ronghui Xu4,5, Christina D Chambers1,4. 1. School of Medicine, Department of Pediatrics, University of California, San Diego, La Jolla, CA. 2. College of Global Public Health, New York University, New York, NY. 3. Skaggs School of Pharmacy and Pharmaceutical Sciences, Division of Clinical Pharmacy, University of California, San Diego, La Jolla, CA. 4. School of Medicine, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA. 5. Department of Mathematics, University of California, San Diego, La Jolla, CA.
Abstract
BACKGROUND: There are limited data regarding the comparability of medication exposure information during pregnancy from maternal report and medical records, including for rheumatoid arthritis and asthma-related medications. METHODS: This study included pregnant women with rheumatoid arthritis (n = 216) and asthma (n = 172) enrolled in the MothertoBaby Pregnancy Studies (2009-2014). Women reported types and dates of medications used through semi-structured telephone interviews up to three times during pregnancy and once after delivery, and medical records were obtained. We calculated Cohen's kappa coefficients and 95% confidence intervals (CIs) and per cent agreement for agreement between report and records. RESULTS: For rheumatoid arthritis, prednisone was reported most frequently (53%). During pregnancy, kappa coefficients for rheumatoid arthritis medications ranged from 0.32 (95% CI 0.15, 0.50) for ibuprofen, with 84.3% agreement, to 0.90 (95% CI 0.84, 0.96) for etanercept with 95.4% agreement, and was 0.44 (95% CI 0.33, 0.55) for prednisone, with 71.3% agreement. For asthma, albuterol was reported most frequently (77.9%). During pregnancy, kappa coefficients for asthma medications ranged from 0.21 (95% CI 0.08, 0.35), with 64.5% agreement for albuterol to 0.84 (95% CI 0.71, 0.96) for budesonide/formoterol, with 96.5% agreement. Where kappas for any use during pregnancy were less than excellent (i.e. ≤0.80), medication use was more frequently captured by report than record. CONCLUSIONS: Agreement was higher for medications typically used continuously than sporadically. Information on medication use from medical records alone may not be adequate when studying the impact of intermittently used medications during pregnancy on perinatal outcomes.
BACKGROUND: There are limited data regarding the comparability of medication exposure information during pregnancy from maternal report and medical records, including for rheumatoid arthritis and asthma-related medications. METHODS: This study included pregnant women with rheumatoid arthritis (n = 216) and asthma (n = 172) enrolled in the MothertoBaby Pregnancy Studies (2009-2014). Women reported types and dates of medications used through semi-structured telephone interviews up to three times during pregnancy and once after delivery, and medical records were obtained. We calculated Cohen's kappa coefficients and 95% confidence intervals (CIs) and per cent agreement for agreement between report and records. RESULTS: For rheumatoid arthritis, prednisone was reported most frequently (53%). During pregnancy, kappa coefficients for rheumatoid arthritis medications ranged from 0.32 (95% CI 0.15, 0.50) for ibuprofen, with 84.3% agreement, to 0.90 (95% CI 0.84, 0.96) for etanercept with 95.4% agreement, and was 0.44 (95% CI 0.33, 0.55) for prednisone, with 71.3% agreement. For asthma, albuterol was reported most frequently (77.9%). During pregnancy, kappa coefficients for asthma medications ranged from 0.21 (95% CI 0.08, 0.35), with 64.5% agreement for albuterol to 0.84 (95% CI 0.71, 0.96) for budesonide/formoterol, with 96.5% agreement. Where kappas for any use during pregnancy were less than excellent (i.e. ≤0.80), medication use was more frequently captured by report than record. CONCLUSIONS: Agreement was higher for medications typically used continuously than sporadically. Information on medication use from medical records alone may not be adequate when studying the impact of intermittently used medications during pregnancy on perinatal outcomes.
Authors: Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz Journal: Am J Obstet Gynecol Date: 2011-04-22 Impact factor: 8.661
Authors: Marleen M H J van Gelder; Iris A L M van Rooij; Hermien E K de Walle; Nel Roeleveld; Marian K Bakker Journal: Drug Saf Date: 2013-01 Impact factor: 5.606
Authors: Cheryl S Broussard; Sonja A Rasmussen; Jennita Reefhuis; Jan M Friedman; Michael W Jann; Tiffany Riehle-Colarusso; Margaret A Honein Journal: Am J Obstet Gynecol Date: 2011-02-23 Impact factor: 8.661
Authors: L T de Jong-van den Berg; C M Waardenburg; F M Haaijer-Ruskamp; M N Dukes; H Wesseling Journal: Eur J Clin Pharmacol Date: 1993 Impact factor: 2.953
Authors: Kristin Palmsten; Sonia Hernández-Díaz; Christina D Chambers; Helen Mogun; Sophia Lai; Todd P Gilmer; Krista F Huybrechts Journal: Obstet Gynecol Date: 2015-09 Impact factor: 7.661
Authors: Emily E Petersen; Sonja A Rasmussen; Katherine Lyon Daniel; Mahsa M Yazdy; Margaret A Honein Journal: J Womens Health (Larchmt) Date: 2008-09 Impact factor: 2.681
Authors: Michael Schatz; Christine A Sorkness; James T Li; Philip Marcus; John J Murray; Robert A Nathan; Mark Kosinski; Trudy B Pendergraft; Priti Jhingran Journal: J Allergy Clin Immunol Date: 2006-03 Impact factor: 10.793
Authors: Kristin Palmsten; Gretchen Bandoli; Gabriela Vazquez-Benitez; Christina D Chambers Journal: Arthritis Care Res (Hoboken) Date: 2022-05-20 Impact factor: 5.178
Authors: Jani van der Hoven; Elizabeth Allen; Annibale Cois; Renee de Waal; Gary Maartens; Landon Myer; Thokozile Malaba; Hlengiwe Madlala; Dorothy Nyemba; Florence Phelanyane; Andrew Boulle; Ushma Mehta; Emma Kalk Journal: BMC Pregnancy Childbirth Date: 2022-06-03 Impact factor: 3.105
Authors: Kristin Palmsten; Matthieu Rolland; Mary F Hebert; Megan E B Clowse; Michael Schatz; Ronghui Xu; Christina D Chambers Journal: Pharmacoepidemiol Drug Saf Date: 2018-02-28 Impact factor: 2.890
Authors: Jordan A Killion; Christina Chambers; Chelsey J F Smith; Gretchen Bandoli Journal: Rheumatology (Oxford) Date: 2022-04-11 Impact factor: 7.046